Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CD30 Expression in Aggressive B-Cell Lymphomas

Clin Lymphoma Myeloma Leuk; ePub 2016 May; Malysz, et al

Publish date:: May 18, 2016

Brentuximab vedotin showed possible benefit in treating certain aggressive B-cell lymphomas in a study involving 116 individuals.

Investigators evaluated CD30 expression in the participants, each of whom had one of the following types of aggressive B-cell lymphoma: Burkitt lymphomas, high grade follicular lymphomas, mixed FL3/DLBCL, post-transplant lymphoproliferative disease type large B-cell lymphomas, or primary mediastinal large B-cell lymphomas.

CD30 expression occurred in 38% of diffuse large B-cell lymphomas. It also occurred in 42% of other non-DLBCL aggressive B-cell lymphomas.

Citation: Malysz J, Erdman P, Klapper J, Zhu J, Creer M, Bayerl M. Clinical implications of CD30 expression in aggressive B-cell lymphomas. [Published online ahead of print May 9, 2016]. Clin Lymphoma Myeloma Leuk. doi:http://dx.doi.org/10.1016/j.clml.2016.04.011.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,